HAI or IV of Adebrelimab, Combined with Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

Hepatic arterial infusion (HAI) of Adebrelimab (ADE) (1200mg, IA, Q3W)

intravenous infusion (IV) of Adebrelimab (ADE) (1200mg, IV, Q3W)

intravenous infusion (IV) of Bevacizumab (Bev.) (15mg/kg, IV, Q3W)

HAIC with FOLFOX regimen (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2500 mg/m2 for 46 hours via hepatic artery Q4W)

The two arms continue the triple combination treatment up to 6 cycles and then received receive intravenous combination therapy of adebrelimab and bevacizumab for maintainance until disease progression or intolerable toxicity